These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 27481879)

  • 1. Pharmacokinetics and Exposure-response Relationship of Golimumab in Patients with Moderately-to-severely Active Ulcerative Colitis: Results from Phase 2/3 PURSUIT Induction and Maintenance Studies.
    Detrez I; Gils A
    J Crohns Colitis; 2017 Jan; 11(1):1-2. PubMed ID: 27481879
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacokinetics and Exposure-response Relationship of Golimumab in Patients with Moderately-to-Severely Active Ulcerative Colitis: Results from Phase 2/3 PURSUIT Induction and Maintenance Studies.
    Adedokun OJ; Xu Z; Marano CW; Strauss R; Zhang H; Johanns J; Zhou H; Davis HM; Reinisch W; Feagan BG; Rutgeerts P; Sandborn WJ
    J Crohns Colitis; 2017 Jan; 11(1):35-46. PubMed ID: 27440869
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis.
    Sandborn WJ; Feagan BG; Marano C; Zhang H; Strauss R; Johanns J; Adedokun OJ; Guzzo C; Colombel JF; Reinisch W; Gibson PR; Collins J; Järnerot G; Rutgeerts P;
    Gastroenterology; 2014 Jan; 146(1):96-109.e1. PubMed ID: 23770005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population Pharmacokinetics and Exposure-Response Modeling of Golimumab in Adults With Moderately to Severely Active Ulcerative Colitis.
    Adedokun OJ; Xu Z; Liao S; Strauss R; Reinisch W; Feagan BG; Sandborn WJ
    Clin Ther; 2020 Jan; 42(1):157-174.e4. PubMed ID: 31982148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis.
    Sandborn WJ; Feagan BG; Marano C; Zhang H; Strauss R; Johanns J; Adedokun OJ; Guzzo C; Colombel JF; Reinisch W; Gibson PR; Collins J; Järnerot G; Hibi T; Rutgeerts P;
    Gastroenterology; 2014 Jan; 146(1):85-95; quiz e14-5. PubMed ID: 23735746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Golimumab: clinical update on its use for ulcerative colitis.
    Gilardi D; Fiorino G; Allocca M; Bravatà I; Danese S
    Drugs Today (Barc); 2015 Mar; 51(3):171-84. PubMed ID: 25876561
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Golimumab for moderately to severely active ulcerative colitis.
    Kedia S; Ahuja V; Makharia GK
    Expert Rev Clin Pharmacol; 2016 Oct; 9(10):1273-82. PubMed ID: 27498886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early Dose Optimisation of Golimumab in Nonresponders to Induction Treatment for Ulcerative Colitis Is Effective and Supported by Pharmacokinetic Data.
    Philip G; Cornillie F; Adedokun JO; Melsheimer R; Rutgeerts P; Colombel JF; Marano C
    J Crohns Colitis; 2019 Sep; 13(10):1257-1264. PubMed ID: 30847474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population Pharmacokinetics and Exposure-Response Modeling Analyses of Golimumab in Children With Moderately to Severely Active Ulcerative Colitis.
    Xu Y; Adedokun OJ; Chan D; Hu C; Xu Z; Strauss RS; Hyams JS; Turner D; Zhou H
    J Clin Pharmacol; 2019 Apr; 59(4):590-604. PubMed ID: 30536638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomised clinical trial: a placebo-controlled study of intravenous golimumab induction therapy for ulcerative colitis.
    Rutgeerts P; Feagan BG; Marano CW; Padgett L; Strauss R; Johanns J; Adedokun OJ; Guzzo C; Zhang H; Colombel JF; Reinisch W; Gibson PR; Sandborn WJ;
    Aliment Pharmacol Ther; 2015 Sep; 42(5):504-14. PubMed ID: 26119226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Subcutaneous Golimumab in Pediatric Ulcerative Colitis: Pharmacokinetics and Clinical Benefit.
    Hyams JS; Chan D; Adedokun OJ; Padgett L; Turner D; Griffiths A; Veereman G; Heyman MB; Rosh JR; Wahbeh G; Strauss R
    Inflamm Bowel Dis; 2017 Dec; 23(12):2227-2237. PubMed ID: 29140944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost per remission and cost per response with infliximab, adalimumab, and golimumab for the treatment of moderately-to-severely active ulcerative colitis.
    Toor K; Druyts E; Jansen JP; Thorlund K
    J Med Econ; 2015 Jun; 18(6):437-46. PubMed ID: 25629655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Golimumab Therapy in Ulcerative Colitis].
    Moon W
    Korean J Gastroenterol; 2016 Feb; 67(2):64-73. PubMed ID: 26907481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic Drug Monitoring of Golimumab in the Treatment of Ulcerative Colitis.
    Vande Casteele N; Khanna R
    Pharm Res; 2017 Aug; 34(8):1556-1563. PubMed ID: 28374338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-Term Benefit of Golimumab for Patients with Moderately to Severely Active Ulcerative Colitis: Results from the PURSUIT-Maintenance Extension.
    Reinisch W; Gibson PR; Sandborn WJ; Feagan BG; Strauss R; Johanns J; Padgett L; Adedokun OJ; Colombel JF; Collins J; Rutgeerts P; Tarabar D; Marano C
    J Crohns Colitis; 2018 Aug; 12(9):1053-1066. PubMed ID: 29917070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short-term effectiveness of golimumab for ulcerative colitis: Observational multicenter study.
    Bosca-Watts MM; Cortes X; Iborra M; Huguet JM; Sempere L; Garcia G; Gil R; Garcia M; Muñoz M; Almela P; Maroto N; Paredes JM
    World J Gastroenterol; 2016 Dec; 22(47):10432-10439. PubMed ID: 28058024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IBD: Golimumab in ulcerative colitis: a 'ménage à trois' of drugs.
    Danese S
    Nat Rev Gastroenterol Hepatol; 2013 Sep; 10(9):511-2. PubMed ID: 23897288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Initial experience with golimumab in clinical practice for ulcerative colitis.
    Castro-Laria L; Argüelles-Arias F; García-Sánchez V; Benítez JM; Fernández-Pérez R; Trapero-Fernández AM; Gallardo-Sánchez F; Pallarés-Manrique H; Gómez-García M; Cabello-Tapia MJ; Talavera-Fabuel A; Bejarano-García A; Leo-Carnerero E; Hernández-Martínez Á; Caunedo-Álvarez Á; Herrerías-Gutiérrez JM
    Rev Esp Enferm Dig; 2016 Mar; 108(3):129-32. PubMed ID: 26786341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Population Pharmacokinetic and Exposure-Response Model of Golimumab for Targeting Endoscopic Remission in Patients With Ulcerative Colitis.
    Dreesen E; Kantasiripitak W; Detrez I; Stefanović S; Vermeire S; Ferrante M; Bouillon T; Drobne D; Gils A
    Inflamm Bowel Dis; 2020 Mar; 26(4):570-580. PubMed ID: 31372650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Letter: effectiveness of golimumab to induce remission in outpatient ulcerative colitis in Italy.
    Tursi A; Della Valle N; Penna A; Pranzo G; Ricciardelli C; Picchio M
    Aliment Pharmacol Ther; 2016 Mar; 43(5):657-8. PubMed ID: 26843348
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.